OtherHot Topics (Invitation Only)
Exploiting the Full Potential of Beta-Amyloid and Tau PET Imaging for Drug Efficacy Testing
Henryk Barthel, John Seibyl, Adriaan A. Lammertsma, Victor L Villemagne and Osama Sabri
Journal of Nuclear Medicine May 2020, jnumed.119.228346; DOI: https://doi.org/10.2967/jnumed.119.228346
Henryk Barthel
1 Leipzig University, Germany;
John Seibyl
2 Institute for Neurodegenerative Disorders;
Adriaan A. Lammertsma
3 VU University Medical Center;
Victor L Villemagne
4 Austin Hospital, The University of Melbourne;
Osama Sabri
5 University Hospital Leipzig


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Journal of Nuclear Medicine
Vol. 66, Issue 2
February 1, 2025
Exploiting the Full Potential of Beta-Amyloid and Tau PET Imaging for Drug Efficacy Testing
Henryk Barthel, John Seibyl, Adriaan A. Lammertsma, Victor L Villemagne, Osama Sabri
Journal of Nuclear Medicine May 2020, jnumed.119.228346; DOI: 10.2967/jnumed.119.228346
Jump to section
Related Articles
Cited By...
- Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders
- {alpha}-Synuclein PET and Parkinson Disease Therapeutic Trials: Ever the Twain Shall Meet?
- First Tau PET Tracer Approved: Toward Accurate In Vivo Diagnosis of Alzheimer Disease